Day: October 17, 2024

FREDERICK, Md., Oct. 17, 2024 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination technologies, today announced that its iHP Corporate Service division is expected to recognize revenues of approximately $650,000 for the three month ended September 30, 2024. This marks a record for the division’s quarterly performance, surpassing historical averages of approximately $250,000 per quarter or $1 million annually. TOMI intends to announce its full Q3 financial results, including total revenue for the third quarter on October 30th, 2024. The division’s significant revenue growth in the third quarter reflects the rising demand for TOMI’s iHP services, particularly within the life sciences sector. TOMI has effectively expanded its marketshare, strengthening...

NOT FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MARKHAM, Ontario, Oct. 17, 2024 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced today that it has completed its previously announced offering (the “Offering”) of $150 million aggregate principal amount of series D senior unsecured debentures (the “Debentures”). The Offering was led by BMO Capital Markets, TD Securities Inc. and CIBC Capital Markets, as joint lead agents and bookrunners. The Debentures were issued at par, bear interest at a rate of 4.436% per annum and will mature on October 17, 2029. The Debentures are rated “BBB (Stable)” by Morningstar DBRS. Sienna intends to use the net proceeds from the Offering to repay existing indebtedness and for general corporate purposes. “This debenture...

WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039. Istaroxime is...

Company welcomes additional recycling technology to its portfolioA group of employees stands inside APK AG’s factory in Merseburg, Germany, now part of LyondellBasellPhoto credit: LyondellBasellAmbition to further develop solvent-based recycling technology and bring to commercial scale Company secures future of employees and fosters expertise with full integration Plant to be transformed into post-consumer plastic waste recyclingROTTERDAM, The Netherlands, Oct. 17, 2024 (GLOBE NEWSWIRE) — LyondellBasell (LYB) today announced it became full owner of APK AG in Merseburg, Germany. APK will be fully integrated and continue as part of LYB, a sustainability leader in the chemical industry. It is LYB’s ambition to further develop the company’s unique solvent-based technology for low density polyethylene (LDPE) and build commercial...

MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Friday, November 8, 2024. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 9923172Webcast: Available on the events section of the Ocugen investor site A replay of the call and archived webcast will be available for approximately...

Apollo Tyres, Ltd Awards SemiCab Scalable Pilot Contract for Transportation Services in India Fort Lauderdale, FL, Oct. 17, 2024 (GLOBE NEWSWIRE) — Algorhythm Holdings, Inc. (“Algorhythm”) (NASDAQ: RIME), an AI-driven technology and consumer electronics holding company, announced today that SemiCab, Inc.’s subsidiary, SMCB Private Solutions Limited (“SemiCab India”), has entered into a master service agreement (MSA) with Apollo Tyres, Ltd. (“Apollo”), India’s largest tire manufacturer. As a top 10 global tire producer, Apollo generated over $3 billion in sales in 2023, operating in more than 100 countries across Asia, Europe, and North America. Algorhythm’s subsidiary SemiCab Holdings, LLC (“SemiCab”) will provide enterprise-level software services to SemiCab India to provide its AI-powered platform, designed to reduce service...

Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are currently being dosed in Part B of the Phase 2 study which will investigate a longer treatment duration NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced encouraging preliminary electroencephalography (EEG) biomarker results from the Part A of the ongoing placebo-controlled...